# Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

> **NCT03049189** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **ITM Solucin GmbH** · enrollment: 324 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 177Lu-edotreotide PRRT
- **DRUG:** Everolimus
- **OTHER:** Amino-Acid Solution

## Key facts

- **NCT ID:** NCT03049189
- **Lead sponsor:** ITM Solucin GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-02
- **Primary completion:** 2024-11-27
- **Final completion:** 2029-11
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03049189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03049189, "Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03049189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*